AMGN vs VRTX
AMGN and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | AMGNAmgen Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $251.99B | $141.70B |
| P/E (TTM) | 29.0 | 32.6 |
| P/B | 21.56 | 7.00 |
| P/S | 6.9x | 11.8x |
| Dividend yield | 2.03% | — |
| Revenue | $38.09B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 10.0% | 8.9% |
| Net income | $8.74B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 88.5% | 838.1% |
| EPS, diluted | $16.10(TTM) | $17.17(TTM) |
| EBIT margin | 24.7% | 34.8% |
| ROE | 66.0% | 19.5% |
| ROIC | 15.1% | 25.0% |
| 1y total return | +62.9% | +33.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: AMGN vs VRTX
| Metric | AMGN | VRTX |
|---|---|---|
| End value | $42.1K | $65.8K |
| Total return | +320.8% | +557.5% |
| CAGR | +14.9% | +20.0% |
| Volatility | 25.1% | 32.6% |
| Sharpe | 0.51 | 0.60 |
| Sortino | 0.76 | 0.88 |
| Max drawdown | -24.9% | -41.6% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)